Two new members—Eli Lilly Canada and Pfizer Inc—have joined the
Structural Genomics Consortium, and new funding was announced this week
for the open-access research project. Members of the consortium forego
early-stage patents, focusing on collaborative research up to Phase I
trials with the intention of extending the cooperation into Phase II. If
the approach proves successful, it could pave the way for a new
standard in drug research and help speed the development of innovative
lifesaving medicines, while saving drug sponsors time and money.
Read more: